FDA user fee endgame, East-West Summit & Biogen: a BioCentury podcast
User fee legislation approaches a critical deadline in Congress; plus key milestones ahead for Biogen
By Jeff Cranmer, Executive Editor
September 27, 2022 12:54 AM UTC
Everything’s at stake for FDA as user fee legislation approaches a critical deadline this week, Washington Editor Steve Usdin says on the latest episode of BioCentury This Week. Usdin details the next steps in the process, which FDA reforms are being dropped from the “clean” user fee bill and the future of healthcare legislation.
BioCentury’s editorial team also recaps the top takeaways from Global Blood Therapeutics Inc. (NASDAQ:GBT) CEO Ted Love’s appearance on The BioCentury Show, previews the upcoming BioCentury-BayHelix East-West Biopharma Summit and assesses two upcoming milestones for Biogen Inc. (NASDAQ:BIIB): an FDA decision on tofersen for amyotrophic lateral sclerosis (ALS) and Phase III data for Alzheimer’s therapy lecanemab that’s due from partner Eisai Co. Ltd. (Tokyo:4523).
